



PRIX GALIEN BRIDGES

CHARTER OF THE PRIX GALIEN BRIDGES COMMITTEE



The Prix Galien was created in 1970 in the memory of Claudius Galenus (129 – 216 AD) who many consider one of the fathers of the modern medicine and pharmacology. The Prix Galien rewards excellence and novelty, and awards additional honors to those who show great promise in the fields of innovative therapeutics, and who have served humanity at large. The pharmaceutical, biotechnology, diagnostics, medical device and digital health solutions considered for Prix Galien Bridges Awards shall have been based on innovative science, developed by synthetic chemistry or molecular biology, manufactured to precise specifications, tested in controlled clinical trials and marketed by ethical life sciences companies. To be eligible, products and solutions must have received approval from a national or regional regulatory authority by December 31 of the year preceding the award, but not more than five years earlier than December 31 of that year, unless the award is for a new and innovative indication, which must have been added within the previous five years.

Prix Galien Bridges Awards shall showcase the Nordic region's long history of creativity and innovation, building strategic bridges to facilitate expertise and knowledge transfers around the Nordic region's innovation precedents and best practices with five strategic and innovative partner countries: Austria, Israel, The Netherlands, Portugal, and Spain. The committee will award six prizes for therapeutics: the Best Pharmaceutical Agent (i.e. small molecule), the Best Biotechnology Product, the Best Medical Technology (including Diagnostic tools and Digital Health Solutions), the Best AI Advances in Human Health, the Best Public Sector Innovation, and the Best Product for Rare/Orphan Diseases approved in the past five years. As to the science, candidates will be chosen from among all therapeutic categories— and each will be judged against all of the others.

The prizes will be awarded for Life Science Innovations that improve the human condition, principally based on two criteria:

- * What was innovative in the course of this product's scientific development, application or clinical utility?
- * What was learned for the future of biomedical science from this product's introduction to the clinic?

Criteria that will not be considered are the size of the market, the size of the company, the cost of development or the contingencies of distribution. Other new awards, consistent with the mission of the Galien Foundation, may be planned. At the discretion of the committee, these awards will be judged by the committee members. The awards committee will be composed of top scientists and potentially an honorary member chosen by the Board of the Galien Foundation. Committee members will generally serve for one, (or a maximum of two) three-year terms. Membership duration will be staggered. Members will be highly distinguished individuals from the scientific and research communities of the Prix Galien Bridges focal countries: Denmark, Finland, Iceland, Norway and Sweden, as well as Austria, Israel, The Netherlands, Portugal, and Spain. In addition to outstanding academic credentials, committee members must have demonstrated expertise and understanding of human therapeutics and must be familiar with healthcare issues in Nordics+ countries. The Board, in consultation with the committee, will choose a Chair, who will serve for two years. The Board will entertain nominations for the committee from current committee members, former committee members, the academic and research communities, and from the scientific divisions of companies engaged in the development of human therapeutics.

The decisions of the independent committee with respect to the choice of winners for awards will be final and wholly the decision of the committee. The committee deliberations will be conducted in private, and without any input whatsoever from the Board of the Foundation, or from Member organizations or other sponsors.